Cargando…

Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline

PURPOSE: To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. METHODS: The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer c...

Descripción completa

Detalles Bibliográficos
Autores principales: Arrossi, Silvina, Temin, Sarah, Garland, Suzanne, Eckert, Linda O’Neal, Bhatla, Neerja, Castellsagué, Xavier, Alkaff, Sharifa Ezat, Felder, Tamika, Hammouda, Doudja, Konno, Ryo, Lopes, Gilberto, Mugisha, Emmanuel, Murillo, Rául, Scarinci, Isabel C., Stanley, Margaret, Tsu, Vivien, Wheeler, Cosette M., Adewole, Isaac Folorunso, de Sanjosé, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646902/
https://www.ncbi.nlm.nih.gov/pubmed/29094100
http://dx.doi.org/10.1200/JGO.2016.008151
_version_ 1783272170316627968
author Arrossi, Silvina
Temin, Sarah
Garland, Suzanne
Eckert, Linda O’Neal
Bhatla, Neerja
Castellsagué, Xavier
Alkaff, Sharifa Ezat
Felder, Tamika
Hammouda, Doudja
Konno, Ryo
Lopes, Gilberto
Mugisha, Emmanuel
Murillo, Rául
Scarinci, Isabel C.
Stanley, Margaret
Tsu, Vivien
Wheeler, Cosette M.
Adewole, Isaac Folorunso
de Sanjosé, Silvia
author_facet Arrossi, Silvina
Temin, Sarah
Garland, Suzanne
Eckert, Linda O’Neal
Bhatla, Neerja
Castellsagué, Xavier
Alkaff, Sharifa Ezat
Felder, Tamika
Hammouda, Doudja
Konno, Ryo
Lopes, Gilberto
Mugisha, Emmanuel
Murillo, Rául
Scarinci, Isabel C.
Stanley, Margaret
Tsu, Vivien
Wheeler, Cosette M.
Adewole, Isaac Folorunso
de Sanjosé, Silvia
author_sort Arrossi, Silvina
collection PubMed
description PURPOSE: To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. METHODS: The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. RESULTS: Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ≥ 75%. RECOMMENDATIONS: In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ≥ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ≥ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus–related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
format Online
Article
Text
id pubmed-5646902
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-56469022017-11-01 Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline Arrossi, Silvina Temin, Sarah Garland, Suzanne Eckert, Linda O’Neal Bhatla, Neerja Castellsagué, Xavier Alkaff, Sharifa Ezat Felder, Tamika Hammouda, Doudja Konno, Ryo Lopes, Gilberto Mugisha, Emmanuel Murillo, Rául Scarinci, Isabel C. Stanley, Margaret Tsu, Vivien Wheeler, Cosette M. Adewole, Isaac Folorunso de Sanjosé, Silvia J Glob Oncol Special Articles PURPOSE: To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. METHODS: The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. RESULTS: Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ≥ 75%. RECOMMENDATIONS: In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ≥ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ≥ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus–related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines. American Society of Clinical Oncology 2017-03-17 /pmc/articles/PMC5646902/ /pubmed/29094100 http://dx.doi.org/10.1200/JGO.2016.008151 Text en © 2017 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Special Articles
Arrossi, Silvina
Temin, Sarah
Garland, Suzanne
Eckert, Linda O’Neal
Bhatla, Neerja
Castellsagué, Xavier
Alkaff, Sharifa Ezat
Felder, Tamika
Hammouda, Doudja
Konno, Ryo
Lopes, Gilberto
Mugisha, Emmanuel
Murillo, Rául
Scarinci, Isabel C.
Stanley, Margaret
Tsu, Vivien
Wheeler, Cosette M.
Adewole, Isaac Folorunso
de Sanjosé, Silvia
Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
title Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
title_full Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
title_fullStr Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
title_full_unstemmed Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
title_short Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
title_sort primary prevention of cervical cancer: american society of clinical oncology resource-stratified guideline
topic Special Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646902/
https://www.ncbi.nlm.nih.gov/pubmed/29094100
http://dx.doi.org/10.1200/JGO.2016.008151
work_keys_str_mv AT arrossisilvina primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT teminsarah primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT garlandsuzanne primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT eckertlindaoneal primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT bhatlaneerja primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT castellsaguexavier primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT alkaffsharifaezat primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT feldertamika primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT hammoudadoudja primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT konnoryo primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT lopesgilberto primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT mugishaemmanuel primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT murilloraul primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT scarinciisabelc primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT stanleymargaret primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT tsuvivien primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT wheelercosettem primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT adewoleisaacfolorunso primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline
AT desanjosesilvia primarypreventionofcervicalcanceramericansocietyofclinicaloncologyresourcestratifiedguideline